↓ Skip to main content

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease

Overview of attention for article published in Cochrane database of systematic reviews, September 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
Published in
Cochrane database of systematic reviews, September 2016
DOI 10.1002/14651858.cd003733.pub4
Pubmed ID
Authors

Jennifer M Knight-Madden, Ian R Hambleton

Abstract

Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome. This is an update of a previously published Cochrane Review. To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 11 July 2016. Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline. We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease. We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease. If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 3%
United States 2 3%
India 1 1%
Chile 1 1%
Canada 1 1%
Unknown 60 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 34%
Student > Postgraduate 7 10%
Student > Master 7 10%
Unspecified 6 9%
Student > Ph. D. Student 6 9%
Other 17 25%
Unknown 1 1%
Readers by discipline Count As %
Medicine and Dentistry 40 60%
Unspecified 9 13%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Social Sciences 4 6%
Nursing and Health Professions 3 4%
Other 6 9%
Unknown 1 1%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2016.
All research outputs
#10,024,075
of 12,527,219 outputs
Outputs from Cochrane database of systematic reviews
#8,906
of 8,923 outputs
Outputs of similar age
#186,124
of 264,396 outputs
Outputs of similar age from Cochrane database of systematic reviews
#166
of 182 outputs
Altmetric has tracked 12,527,219 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,396 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 182 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.